What Is M-M-R II? Uses, Dosage, and What You Need to Know in 2026

M-M-R II is one of the most well-known vaccines in the world — but many patients (and parents) have questions about exactly what it is, who needs it, how it works, and whether it is still relevant in 2026. This article answers all of those questions clearly.

What Is M-M-R II?

M-M-R II is the brand name for the Measles, Mumps, and Rubella Virus Vaccine Live manufactured by Merck Sharp & Dohme LLC. It is a live-attenuated combination vaccine — meaning it contains weakened (but live) forms of all three viruses. When injected, it stimulates the immune system to produce antibodies against measles, mumps, and rubella without causing the diseases themselves.

The vaccine has been in use in the United States since the 1970s and has a well-established safety and efficacy record spanning more than 40 years. It is one of the most important public health tools for controlling three historically devastating childhood diseases.

What Does M-M-R II Protect Against?

M-M-R II protects against three viral diseases:

Measles (rubeola): A highly contagious respiratory virus that spreads through air. Measles can cause pneumonia, encephalitis (brain inflammation), and death. Before widespread vaccination, measles caused an estimated 2.6 million deaths per year globally. Two doses of MMR are approximately 97% effective at preventing measles.

Mumps: A viral infection causing swelling of the salivary glands (parotitis), and potentially the testicles in males (orchitis), the brain (viral meningitis or encephalitis), and the pancreas. Two doses of MMR are approximately 88% effective against mumps.

Rubella (German measles): Often mild in children, but extremely dangerous when contracted during pregnancy. Congenital Rubella Syndrome (CRS) can cause deafness, cataracts, heart defects, and intellectual disabilities in babies born to infected mothers. Two doses are approximately 97% effective.

Who Should Get M-M-R II?

The CDC recommends M-M-R II (or PRIORIX) for:

All children: Two doses: the first at 12-15 months of age, the second at 4-6 years of age

Adults born in 1957 or later: Should have documentation of at least one MMR dose. Two doses are recommended for healthcare workers, students in post-secondary schools, international travelers, and others at higher risk.

Adults born before 1957: Generally considered immune to measles and mumps based on presumed prior exposure (though vaccination is still recommended for healthcare workers)

International travelers: Infants 6-11 months traveling internationally should receive one early dose; children 12 months and older and adults with evidence of susceptibility should receive 2 doses

Women of childbearing age: Should confirm rubella immunity before becoming pregnant. If not immune, receive MMR after completing or terminating pregnancy.

Dosage and How It Is Given

M-M-R II comes as a lyophilized (freeze-dried) powder that is reconstituted with sterile diluent before administration. Each dose is approximately 0.5 mL, given by subcutaneous or intramuscular injection (preferably into the outer upper arm). The dose is the same for children and adults.

The recommended two-dose schedule for children:

Dose 1: 12-15 months of age

Dose 2: 4-6 years of age (the second dose can be given earlier, at least 28 days after the first dose, if needed)

For post-exposure prophylaxis after measles exposure, a dose of M-M-R II should be administered within 72 hours of exposure in eligible individuals.

Who Should NOT Get M-M-R II?

M-M-R II is contraindicated for:

Pregnant women (and women should avoid pregnancy for at least 1 month after vaccination)

Severely immunocompromised individuals (due to disease, chemotherapy, or immunosuppressive medications)

People with a history of anaphylaxis to neomycin or gelatin (both are components of the vaccine)

People with active untreated tuberculosis

People with moderate or severe febrile illness (defer vaccination until recovered)

Why Is M-M-R II Relevant in 2026?

Despite the availability of effective vaccines for decades, measles made a significant comeback in the United States in 2025. Research published in Nature Health (2026) found counties with MMR vaccination coverage below 60% — well below the 95% threshold needed for measles herd immunity. Cases spread across multiple states, and the 2025 outbreak in Texas and New Mexico resulted in fatalities.

M-M-R II is not an "old" vaccine that is no longer needed — it is critically relevant in 2026, particularly for unvaccinated adults, catch-up immunization, and community immunity protection.

If you are having trouble finding M-M-R II at your local pharmacy, medfinder can call pharmacies near you to locate available stock.

Related: M-M-R II Side Effects: What to Expect and When to Call Your Doctor